Revenio Group Oyj (HEL:REG1V)
Finland · Delayed Price · Currency is EUR | Market Cap | 330.47M -47.5% |
| Revenue (ttm) | 124.35M +16.0% |
| Net Income | 13.11M -27.5% |
| EPS | 0.49 -27.2% |
| Shares Out | 29.09M |
| PE Ratio | 22.74 |
| Forward PE | 12.80 |
| Dividend | 0.44 (3.87%) |
| Ex-Dividend Date | n/a |
| Volume | 48,729 |
| Open | 11.32 |
| Previous Close | 11.20 |
| Day's Range | 11.08 - 11.40 |
| 52-Week Range | 10.36 - 25.85 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 16.37 (+44.1%) |
| Earnings Date | Nov 12, 2026 |
About Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by vet... [Read more]
Financial Performance
In 2025, Revenio Group Oyj's revenue was 109.85 million, an increase of 5.80% compared to the previous year's 103.82 million. Earnings were 17.41 million, a decrease of -5.87%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for REG1V stock is "Strong Buy." The 12-month stock price target is €16.37, which is an increase of 44.10% from the latest price.
News
Revenio Group Oyj Press release: Status update
Revenio Group Oyj issued a press release on September 29, 2026, disclosing material business information to investors.
Revenio Group Oyj Slides: Status update
Revenio Group Oyj has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Revenio Group Oyj Capital Markets Day Transcript
Revenio Group Oyj Capital Markets Day Transcript
Revenio Group Oyj Transcript: CMD 2026
The company is shifting from vision care to connected eye health, expanding its addressable market and product portfolio through the Visionix acquisition. Financial targets include 5%-10% organic CAGR and 25% adjusted EBITDA by 2029, with significant synergies already realized. Integration efforts focus on commercial, operational, and cultural alignment to drive sustainable growth.
Revenio Group Oyj Slides: FY 2026
Revenio Group Oyj has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 15, 2026.
Revenio Group Oyj Press release: FY 2026
Revenio Group Oyj issued a press release on September 15, 2026, disclosing material business information to investors.
Revenio Group Oyj Earnings Call Transcript: Q2 2026
Integration of Visionix is ahead of schedule, with EUR 5 million in synergies already secured. Q2 net sales rose 48.1% due to the acquisition, but gross margin declined to 65% from 73% last year, mainly due to tariffs and Visionix dilution. 2026 guidance sees net sales of EUR 190–205 million and a satisfactory EBITDA level.
Revenio Group Oyj Quarterly report: Q2 2026
Revenio Group Oyj has published its Q2 2026 quarterly earnings report on September 8, 2026.
Revenio Group Oyj Slides: Q2 2026
Revenio Group Oyj has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 8, 2026.
Revenio Group Oyj Earnings Call Transcript: Q1 2026
Q1 saw 8.4% FX-adjusted sales growth, strong U.S. and Europe performance, but lower operating profit due to Visionix transaction costs. The Visionix acquisition expands the addressable market and product portfolio, with significant synergies and a rights issue planned for H2.
Revenio Group Oyj Quarterly report: Q1 2026
Revenio Group Oyj has published its Q1 2026 quarterly earnings report on April 28, 2026.
Revenio Group Oyj Slides: Q1 2026
Revenio Group Oyj has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Revenio Group Oyj Transcript: M&A announcement
The merger creates a leading ophthalmic diagnostics company with a EUR 2.5 billion accessible market, targeting EUR 20 million in synergies and 25% EBITDA margin by 2028-2029. Integration is structured for rapid synergy capture, with strong shareholder and leadership commitment.
Revenio Group Oyj Slides: M&A announcement
Revenio Group Oyj has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Revenio Group Oyj Press release: M&A announcement
Revenio Group Oyj issued a press release on April 13, 2026, disclosing material business information to investors.
Revenio Group Oyj Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong sales growth, especially in the US and EMEA, with robust cash flow and expanding screening solutions. 2026 guidance projects 8%-15% net sales growth, with profitability supported by price increases and ongoing R&D, despite tariff and clinical trial cost headwinds.
Revenio Group Oyj Annual report: Q4 2025
Revenio Group Oyj has published its Q4 2025 annual report on February 11, 2026.
Revenio Group Oyj Quarterly report: Q4 2025
Revenio Group Oyj has published its Q4 2025 quarterly earnings report on February 11, 2026.
Revenio Group Oyj Slides: Q4 2025
Revenio Group Oyj has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 11, 2026.
Revenio Group Oyj Earnings Call Transcript: Q3 2025
Q3 delivered 8.1% sales growth and 9.1% higher operating profit, driven by strong European and U.S. demand for screening solutions. Guidance is unchanged, with Q4 expected to be the strongest quarter. APAC lagged due to currency headwinds, while new product launches and M&A activity continued.
Revenio Group Oyj Quarterly report: Q3 2025
Revenio Group Oyj has published its Q3 2025 quarterly earnings report on October 30, 2025.
Revenio Group Oyj Slides: Q3 2025
Revenio Group Oyj has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 30, 2025.